President Iñaki Gutierrez-Ibarluzea (Spain), 2019-21

BSc and MSc in Sciences from the University of the Basque Country UPV-EHU, Doctor in Sciences (NeuroScience) from the same university, Masters in Epidemiology from the University of Granada and the Andalusian School of Public Health and Masters in Bioethics from the University Ramon Llul and the Institute Borja of Bioethics. He is the coordinator of the early warning and alert system on new and emerging health technologies of Osteba, Basque Office for Health Technology Assessment. Iñaki is the co-chair of the HTAi IG on Disinvestment and Early Awareness, and a member of the information resources IG of HTAi and the liaison person of the Public Health and Nutrition IG. He has collaborated on the European Union funded projects such as InnoHTA (Innovation and HTA), EUnetHTA (European Network for HTA), PHGEN I and II (Public Health Genomics) ALCOVE (Alzheimer in Europe), PerMed (Personalised Medicine), DISCHARGE and Health Cluster Network, performing different functions. He has also coordinated various projects at the Spanish level such as: GENTecS (Group for the Evaluation of New Technologies in Health) and the Information Resources group.

He was a member of the Board of Directors (2010-2012) and Secretary of the International Society HTAi (2012-2014). He has been the chairman of EuroScan International Network for the identification and evaluation of new and emerging health technologies in the period (2007-2010), vice-chair in the periods (2005-2007) and (2010-2011). He is currently the Vice Chair of EuroScan. Iñaki is also an associated professor in the School of Nursing of Osakidetza Basque Health Service and works with the University of the Basque Country and the Open University of Catalonia in different academic activities. He has also participated as an advisor in different call for funds at the local, regional, country (Spain, Poland, Korea and UK) and the European Union levels (FP7, COST and Horizon 2020). He has been a member of the International Scientific Committee of the Health Innovation Awards of the NHS-North West 2009 (United Kingdom).

He has collaborated with the Spanish Ministry of Industry and the Spanish Observatory for Prospective Technological Studies and is a member and coordinator of the Task Force for Genomics and Public Health. He has also participated as expert advisor in the forum for social cohesion between the EU and Mexico (2010). Recently, he has collaborated with WHO-Europe as expert advisor and evaluator on the program of Medical Devices for Countries with limited resources. Iñaki has been advising different HTA initiatives in Argentina, Brazil, Colombia, Costa Rica, Mexico, South Africa, Tunisia, Israel, the Horizon Scanning initiative of EEUU and Italy, WHO-EMRO region, WHO health technologies unit and is member of the HTA glossary committee. As member of the Basque Ministry of Health Iñaki has relevant experience on Chronic diseases and its management (http://ec.europa.eu/research/innovation-union/pdf/active-healthy-ageing/basque.pdf). In 2016 he served as co-chair of the ISPC of HTAi Tokyo 2017 and he has been member or the ISPCs in HTAi Oslo.

Vice-President Wija Oortwijn (Netherlands), 2019-21

Dr. Wija Oortwijn studied health sciences and holds a PhD in Medicine. Currently, Wija is employed at the Radboud University Medical Centre, Department for Health Evidence, in the field of international HTA. She has more than 25 years of relevant professional experience in HTA and health policy analysis around the globe, with her key expertise including health priority setting, policy evaluation and health services research. Since 1993, she has been extensively involved in the development of HTA and health system strengthening around the world; working with Ministries of Health, the European Commission, World Bank, and World Health Organization (WHO).

Wija was one of the authors of a report describing the organization of HTA in the Netherlands (1995). This report provided important input for Dutch HTA policy. In addition, she co-coordinated and participated in the pioneering EUR-ASSESS project (1994-1997), the first European Commission-funded project to develop coordination of HTA activities in Europe, and its successors, HTA-Europe and ECHAHI/ECHTA. These projects laid the foundation of establishing a formal basis for HTA collaboration in Europe (i.e. EUnetHTA). She has co-authored 10 book chapters concerning different aspects of HTA, edited several journal issues, has written more than 60 other scholarly published papers and has been a keynote speaker at several key HTA events around the globe.

She is a founding member of the Dutch Society for Health Technology Assessment (1995), and a founding member of the Committee for a New Society for Health Technology Assessment that declared the establishment of HTAi in 2003.

Since the establishment of HTAi, Wija has been actively involved in many activities. She served on the HTAi Board (2007-2010), was co-chair of the Interest Group on Ethics (2012-2017) as well as chair of the Committee on Stakeholder Engagement in the Society and its Activities (2016-2017). In addition, she was a member of the international scientific programme committee (ISPC) of several annual meetings and served as the scientific secretary of the HTAi Global Policy Forum from July 2016 until June 2019.

Currently, she is a member of the HTAi Scientific Development and Capacity Building Advisory Committee, and member of several Interest Groups (HTA in Developing Countries, Patient & Citizen Involvement, and Ethics). She is also associate editor of the International Journal of Technology Assessment in Health Care. Finally, she is the co-chair of the INAHTA/HTAi HTA definition Task Group, including representatives from EUnetHTA, HTAsiaLink, RedETSA, WHO, HTA Glossary and ISPOR.

Treasurer Marco Marchetti (Italy), 2018-20

Marco Marchetti graduated in medicine at Università Cattolica del Sacro Cuore (Rome) and postgraduate in Hygiene and Public Health and Legal Medicine.

Since January 1, 2017, he has been the Director of the National Center for the Health Technology Assessment of the Italian National Institute for Health.

He was Director of the Health Technology Assessment and Innovation Unit of the Fondazione Policlinico Universitario “Agostino Gemelli” at the Università Cattolica del Sacro Cuore until December 2016.  He has also been the European Director of the International Master Program in HTA and Management since 2001.

He has been in the period 2007-2015 Director of Scientific-Technical Office of Institutional review board (IRB) – Ethical review board of the Università Cattolica del Sacro Cuore .

He has been assistant to Medical Director of the Policlinico Universitario “Agostino Gemelli” at the Università Cattolica del Sacro Cuore from February 1995 to January 2001.

He has been an expert and referee for Health Technology research proposals in 2003 and 2008 through the NHS Health Technology Assessment Programme, of the National Coordinating Office for Health Technology Assessment in the United Kingdom.

He was in charge of organizing the second HTAi Annual Meeting, “Bringing HTA into Practice,” in June 2005, and was Co-Chair of Local Organizing Committee of the 2017 HTAi Annual Meeting in Rome in June 2017. He is Co-Chair of the HTAi Interest Group Hospital-Based HTA. Since the beginning, he has participated ino the activities of the European Network of Health Technology Assessment.

His areas of expertise  are in the following fields: hospital management, quality assurance, risk management, HTA, drug epidemiology, evidence-based medicine and digital medicine impact evaluation. He has collaborated with the National Agency for Drugs and Regional Government in the assessment process of different drugs and medical devices with a particular focus on innovative pricing scheme and  payment by results. He has  published more than 150 papers on national and international on the subjects he interested in.

Secretary Franz Pichler (Australia), 2018-20

Franz Pichler is a Senior Director in the Global Public Policy group at Eli Lilly and company. He specializes on international health care policy issues relating to Health Technology Assessment (HTA). He supports regional market access policy in Japan, where he chairs the PhRMA Japan Vision Task Force, and in China, where he co-chairs the HTA Working Group of the China R&D Based Pharmaceutical Association Committee (RDPAC). Previously, he has worked on the European HTA policy, including representing Lilly on the EFPIA HTA Working Group, EuropaBio HTA and Market Access Group and as a participant of the IMI GetReal public-private partnership.

Franz has been an active member of HTAi for over ten years. In 2012, Franz co-founded the HTA-Regulatory Interactions Interest Group and chaired this IG until its merger to form the Regulatory Interactions and Conditional Coverage (RICC) Interest Group in 2016. He currently chairs the Business Development Group and is a member of the Scientific Development and Capacity Building (SDCB) Committee and the Asia Policy Forum Organising Committee (APFOC).

Franz joined Lilly in 2012 after serving as the manager of the HTA Programme at the Centre for Innovation in Regulatory Science (CIRS), a non-profit, independent medicines policy and research think tank. Prior to joining CIRS, Franz worked for over 10 years in molecular biology with specialties in functional genomics, population genetics and bioinformatics. He obtained his BSC in biology and PhD in population genetics at the University of Auckland in 1997 and 2002, respectively.